Duodenal Ulcer, Stomach Ulcer
Conditions
Brief summary
This study will determine how if MK0782 is safe and tolerable and to determine how often and the severity of stomach and small intestine ulcers develop following administration of MK0782 plus enteric coated aspirin, rofecoxib 25mg plus enteric coated aspirin, naproxen 500 mg puls enteric coated asprin vs placebo. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Interventions
DRUGMK0782
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or non pregnant female * 18 years of age or older (age at consent) * Able to abstain from alcohol, tobacco, spicy foods, limit coffee * Able to avoid strenuous activity * Able to read and fill out a study diary
Exclusion criteria
* You have participated in an investigational drug study within 4 weeks of entering this study * Your weight is not within a specific range for the study * You have a history of GI problems like a gastric ulcer * You have had gastric or intestinal surgery * You have had abdominal or chest surgery * You are currently abusing drugs or alcohol or have a history of abuse * You have a history of psychiatric disorders * You are a smoker or have smoked during the last year
Outcome results
None listed